PMCC Staff Publications

pmcc logo sml



Here are the staff publications for November 2018.

Compiled by the Health Sciences Library (RMH, RWH, PMCC and Victorian Mental Health) 3rd December 2018.

1. Abu Eta R, Gavriel H, Stephen K, Eviatar E, Yeheskeli E. The significance of tissue biopsy for fungi in necrotizing otitis externa. European Archives of Oto-Rhino-Laryngology 2018;275:2941-5.

2. Aide N, Hicks RJ, Le Tourneau C, Lheureux S, Fanti S, Lopci E. FDG PET/CT for assessing tumour response to immunotherapy : Report on the EANM symposium on immune modulation and recent review of the literature. European Journal of Nuclear Medicine and Molecular Imaging 2019;46:238-50.

3. Aung KL, El-Khoueiry AB, Gelmon K, Tran B, Bajaj G, He B, Chen T, Zhu L, Poojary S, Basak S, Qi Z, Spreafico A, Fischer BS, Desai J. A multi-arm phase I dose escalating study of an oral NOTCH inhibitor BMS-986115 in patients with advanced solid tumours. Investigational New Drugs 2018;36:1026-36.

4. Aziz D, Etemadmoghadam D, Caldon CE, Au-Yeung G, Deng N, Hutchinson R, Bowtell D, Waring P. 19q12 amplified and non-amplified subsets of high grade serous ovarian cancer with overexpression of cyclin E1 differ in their molecular drivers and clinical outcomes. Gynecolic Oncology 2018;151:327-36.

5. Barrientos JC, O'Brien S, Brown JR, Kay NE, Reddy NM, Coutre S, Tam C, Mulligan S, Jaeger U, Devereux S, Pocock C, Robak T, Schuster SJ, Schuh A, Gill D, Bloor A, Dearden C, Moreno C, Cull G, Hamblin M, Jones JA, Eckert K, Solman IG, Suzuki S, Hsu E, James DF, Byrd JC, Hillmen P. Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Clinical Lymphoma, Myeloma & Leukemia 2018;18:803-13.e7.

6. Benn DE, Zhu Y, Andrews KA, Wilding M, Duncan EL, Dwight T, Tothill RW, Burgess J, Crook A, Gill AJ, Hicks RJ, Kim E, Luxford C, Marfan H, Richardson AL, Robinson B, Schlosberg A, Susman R, Tacon L, Trainer A, Tucker K, Maher ER, Field M, Clifton-Bligh RJ. Bayesian approach to determining penetrance of pathogenic SDH variants. Journal of Medical Genetics 2018;55:729-34.

7. Biswas C, Law D, Birch M, Halliday C, Sorrell TC, Rex J, Slavin M, Chen SC. In vitro activity of the novel antifungal compound F901318 against Australian Scedosporium and Lomentospora fungi. Medical Mycology 2018;56:1050-4.

8. Borgmann H, Cooperberg M, Murphy D, Loeb S, N'Dow J, Ribal MJ, Woo H, Roupret M, Winterbottom A, Wijburg C, Wirth M, Catto J, Kutikov A. Online Professionalism-2018 Update of European Association of Urology (@Uroweb) Recommendations on the Appropriate Use of Social Media. European Urology 2018;74:644-50.

9. Bucknell NW, Hardcastle N, Bressel M, Hofman MS, Kron T, Ball D, Siva S. Functional lung imaging in radiation therapy for lung cancer: A systematic review and meta-analysis. Radiotherapy and Oncology 2018;129:196-208.

10. Crispin M, Udovicich C, Chan S, Wong S, Pitcher M. Trends in genetic screening referral in breast cancer patients under the age of forty: 2001-2016. Breast Journal 2018;24:1109-11.

11. Cristofanilli M, DeMichele A, Giorgetti C, Turner NC, Slamon DJ, Im SA, Masuda N, Verma S, Loi S, Colleoni M, Theall KP, Huang X, Liu Y, Bartlett CH. Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3. European Journal of Cancer 2018;104:21-31.

12. Cui W, Stern C, Hickey M, Goldblatt F, Anazodo A, Stevenson WS, Phillips KA. Preventing ovarian failure associated with chemotherapy. Medical Journal of Australia 2018;209:412-6.

13. DeAngelis A, Breik O, Koo K, Iseli T, Nastri A, Fua T, Rischin D, McCullough M, Wiesenfeld D. Non-smoking, non-drinking elderly females, a 5year follow-up of a clinically distinct cohort of oral squamous cell carcinoma patients. Oral Oncology 2018;86:113-20.

14. Ferguson MT, Hofman MS, Ismail H, Melville A, Yap KSK, Hicks RJ, Wright S, Riedel B. A pilot study of cardiopulmonary exercise testing and cardiac stress positron emission tomography before major non-cardiac surgery. Anaesthesia 2018;73:1524-30.

15. Fortuno C, James PA, Spurdle AB. Current review of TP53 pathogenic germline variants in breast cancer patients outside Li-Fraumeni syndrome. Human Mutation 2018;39:1764-73.

16. Freimund AE, Beach JA, Christie EL, Bowtell DDL. Mechanisms of Drug Resistance in High-Grade Serous Ovarian Cancer. Hematology/Oncology Clinics of North America 2018;32:983-96.

17. Gayden T, Sepulveda FE, Khuong-Quang DA, Pratt J, Valera ET, Garrigue A, Kelso S, Sicheri F, Mikael LG, Hamel N, Bajic A, Dali R, Deshmukh S, Dervovic D, Schramek D, Guerin F, Taipale M, Nikbakht H, Majewski J, Moshous D, Charlebois J, Abish S, Bole-Feysot C, Nitschke P, Bader-Meunier B, Mitchell D, Thieblemont C, Battistella M, Gravel S, Nguyen VH, Conyers R, Diana JS, McCormack C, Prince HM, Besnard M, Blanche S, Ekert PG, Fraitag S, Foulkes WD, Fischer A, Neven B, Michonneau D, de Saint Basile G, Jabado N. Germline HAVCR2 mutations altering TIM-3 characterize subcutaneous panniculitis-like T cell lymphomas with hemophagocytic lymphohistiocytic syndrome. Nature Genetics 2018;50:1650-7.

18. Grohmann M, Wiede F, Dodd GT, Gurzov EN, Ooi GJ, Butt T, Rasmiena AA, Kaur S, Gulati T, Goh PK, Treloar AE, Archer S, Brown WA, Muller M, Watt MJ, Ohara O, McLean CA, Tiganis T. Obesity Drives STAT-1-Dependent NASH and STAT-3-Dependent HCC. Cell 2018;175:1289-306.e20.

19. Herschtal A, Martin RF, Leong T, Lobachevsky P, Martin OA. A Bayesian Approach for Prediction of Patient Radiosensitivity. International Journal of Radiation Oncology, Biology, Physics 2018;102:627-34.

20. Hirshoren N, Ruskin O, Fua T, Kleid S, Magarey M, Dixon B. Transoral robotic surgery: implementation as a tool in head and neck surgery - a single-centre Australian experience. ANZ Journal of Surgery 2018;88:1129-34.

21. Hofman MS, Murphy DG, Williams SG, Nzenza T, Herschtal A, Lourenco RA, Bailey DL, Budd R, Hicks RJ, Francis RJ, Lawrentschuk N. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol. BJU International 2018;122:783-93.

22. Hopper JL, Dite GS, MacInnis RJ, Liao Y, Zeinomar N, Knight JA, Southey MC, Milne RL, Chung WK, Giles GG, Genkinger JM, McLachlan SA, Friedlander ML, Antoniou AC, Weideman PC, Glendon G, Nesci S, Andrulis IL, Buys SS, Daly MB, John EM, Phillips KA, Terry MB. Age-specific breast cancer risk by body mass index and familial risk: prospective family study cohort (ProF-SC). Breast Cancer Research 2018;20:132.

23. Kanatsios S, Melanoma Project M, Li Wai Suen CSN, Cebon JS, Gyorki DE. Neutrophil to lymphocyte ratio is an independent predictor of outcome for patients undergoing definitive resection for stage IV melanoma. Journal of Surgical Oncology 2018;118:915-21.

24. Kandolf Sekulovic L, Guo J, Agarwala S, Hauschild A, McArthur G, Cinat G, Wainstein A, Caglevic C, Lorigan P, Gogas H, Alvarez M, Duncombe R, Lebbe C, Peris K, Rutkowski P, Stratigos A, Forsea AM, De La Cruz Merino L, Kukushkina M, Dummer R, Hoeller C, Gorry C, Bastholt L, Herceg D, Neyns B, Vieira R, Arenberger P, Bylaite-Bucinskiene M, Babovic N, Banjin M, Putnik K, Todorovic V, Kirov K, Ocvirk J, Zhukavets A, Ymeri A, Stojkovski I, Garbe C. Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries. European Journal of Cancer 2018;104:201-9.

25. Kok DL, Hendry S, Alvarez B. Iatrogenic subcutaneous metastasis from WHO Grade I intracranial meningioma. Journal of Clinical Neuroscience 2018;58:224-5.

26. Kron T, Donahoo G, Lonski P, Wheeler G. A technique for total skin electron therapy (TSET) of an anesthetized pediatric patient. Journal of Applied Clinical Medical Physics 2018;19:109-16.

27. Kwong JC, Urbancic K, Trubiano JA. Beyond Penicillin: Rapid Desensitization for Specific Flucloxacillin Hypersensitivity. Antimicrobial Agents and Chemotherapy 2018;62.

28. Lawrence MG, Obinata D, Sandhu S, Selth LA, Wong SQ, Porter LH, Lister N, Pook D, Pezaro CJ, Goode DL, Rebello RJ, Clark AK, Papargiris M, Van Gramberg J, Hanson AR, Banks P, Wang H, Niranjan B, Keerthikumar S, Hedwards S, Huglo A, Yang R, Henzler C, Li Y, Lopez-Campos F, Castro E, Toivanen R, Azad A, Bolton D, Goad J, Grummet J, Harewood L, Kourambas J, Lawrentschuk N, Moon D, Murphy DG, Sengupta S, Snow R, Thorne H, Mitchell C, Pedersen J, Clouston D, Norden S, Ryan A, Dehm SM, Tilley WD, Pearson RB, Hannan RD, Frydenberg M, Furic L, Taylor RA, Risbridger GP. Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy. European Urology 2018;74:562-72.

29. Lawrentschuk N. Drowning in ethics for low-risk data: is this best for patients? BJU International 2018;122 Suppl 5:4.

30. Lieng H, Hayden AJ, Christie DRH, Davis BJ, Eade TN, Emmett L, Holt T, Hruby G, Pryor D, Shakespeare TP, Sidhom M, Skala M, Wiltshire K, Yaxley J, Kneebone A. Radiotherapy for recurrent prostate cancer: 2018 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group. Radiotherapy and Oncology 2018;129:377-86.

31. Maertens JA, Girmenia C, Bruggemann RJ, Duarte RF, Kibbler CC, Ljungman P, Racil Z, Ribaud P, Slavin MA, Cornely OA, Peter Donnelly J, Cordonnier C. European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. Journal of Antimicrobial Chemotherapy 2018;73:3221-30.

32. Maleki S, Alexander M, Fua T, Liu C, Rischin D, Lingaratnam S. A systematic review of the impact of outpatient clinical pharmacy services on medication-related outcomes in patients receiving anticancer therapies. Journal of Oncology Pharmacy Practice 2019;25:130-9.

33. McGovern JA, Shafiee A, Wagner F, Lahr CA, Landgraf M, Meinert C, Williams ED, Russell PJ, Clements JA, Loessner D, Holzapfel BM, Risbridger GP, Hutmacher DW. Humanization of the Prostate Microenvironment Reduces Homing of PC3 Prostate Cancer Cells to Human Tissue-Engineered Bone. Cancers 2018;10.

34. Miligy IM, Gorringe KL, Toss MS, Al-Kawaz AA, Simpson P, Diez-Rodriguez M, Nolan CC, Ellis IO, Green AR, Rakha EA. Thioredoxin-interacting protein is an independent risk stratifier for breast ductal carcinoma in situ. Modern Pathology 2018;31:1807-15.

35. Mitchell EL, Lau PKH, Khoo C, Liew D, Leung J, Liu B, Rischin A, Frauman AG, Kee D, Smith K, Brady B, Rischin D, Gibson A, Mileshkin L, Klein O, Weickhardt A, Arulananda S, Shackleton M, McArthur G, Ostor A, Cebon J, Solomon B, Buchanan RR, Wicks IP, Lo S, Hicks RJ, Sandhu S. Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series. European Journal of Cancer 2018;105:88-102.

36. Moloney M, Faulkner D, Link E, Rischin D, Solomon B, Lim AM, Zalcberg JR, Jefford M, Michael M. Feasibility of 5-fluorouracil pharmacokinetic monitoring using the My-5FU PCM system in a quaternary oncology centre. Cancer Chemotherapy and Pharmacology 2018;82:865-76.

37. Ng SP, Khor R, Bressel M, MacManus M, Seymour JF, Hicks RJ, Wirth A. Outcome of patients with early-stage follicular lymphoma staged with (18)F-Fluorodeoxyglucose (FDG) positron emission tomography (PET) and treated with radiotherapy alone. European Journal of Nuclear Medicine and Molecular Imaging 2019;46:80-6.

38. Ni J, Feng J, Denehy L, Wu Y, Xu L, Granger CL. Symptoms of Posttraumatic Stress Disorder and Associated Risk Factors in Patients With Lung Cancer: A Longitudinal Observational Study. Integrative Cancer Therapies 2018;17:1195-203.

39. O'Leary B, Cutts RJ, Liu Y, Hrebien S, Huang X, Fenwick K, Andre F, Loibl S, Loi S, Garcia-Murillas I, Cristofanilli M, Huang Bartlett C, Turner NC. The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial. Cancer Discovery 2018;8:1390-403.

40. Ong WL, Yaxley JW, Millar JL. Brachytherapy-based radiotherapy with androgen deprivation for management of high-risk prostate cancer - time to reverse the declining trend? BJU International 2018;122 Suppl 5:5-6.

41. Perera M, McGrath S, Sengupta S, Crozier J, Bolton D, Lawrentschuk N. Pelvic lymph node dissection during radical cystectomy for muscle-invasive bladder cancer. Nature Reviews Urology 2018;15:686-92.

42. Powles RL, Redmond D, Sotiriou C, Loi S, Fumagalli D, Nuciforo P, Harbeck N, de Azambuja E, Sarp S, Di Cosimo S, Huober J, Baselga J, Piccart-Gebhart M, Elemento O, Pusztai L, Hatzis C. Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial. JAMA Oncology 2018;4:e181564.

43. Prasanna T, Karapetis CS, Roder D, Tie J, Padbury R, Price T, Wong R, Shapiro J, Nott L, Lee M, Chua YJ, Craft P, Piantadosi C, Sorich M, Gibbs P, Yip D. The survival outcome of patients with metastatic colorectal cancer based on the site of metastases and the impact of molecular markers and site of primary cancer on metastatic pattern. Acta Oncologica 2018;57:1438-44.

44. Raiber EA, Portella G, Martinez Cuesta S, Hardisty R, Murat P, Li Z, Iurlaro M, Dean W, Spindel J, Beraldi D, Liu Z, Dawson MA, Reik W, Balasubramanian S. 5-Formylcytosine organizes nucleosomes and forms Schiff base interactions with histones in mouse embryonic stem cells. Nature Chemistry 2018;10:1258-66.

45. Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Dieras V, Hegg R, Im SA, Shaw Wright G, Henschel V, Molinero L, Chui SY, Funke R, Husain A, Winer EP, Loi S, Emens LA. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. New England Journal of Medicine 2018;379:2108-21.

46. Shapiro JD, Thavaneswaran S, Underhill CR, Robledo KP, Karapetis CS, Day FL, Nott LM, Jefford M, Chantrill LA, Pavlakis N, Tebbutt NC, Price TJ, Khasraw M, Van Hazel GA, Waring PM, Tejpar S, Simes J, Gebski VJ, Desai J, Segelov E. Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study. Clinical Colorectal Cancer 2018;17:313-9.

47. Sharpe C, Davis J, Mason K, Tam C, Ritchie D, Koldej R. Comparison of gene expression and flow cytometry for immune profiling in chronic lymphocytic leukaemia. Journal of Immunological Methods 2018;463:97-104.

48. Shepshelovich D, Townsend AR, Espin-Garcia O, Latifovic L, O'Callaghan CJ, Jonker DJ, Tu D, Chen E, Morgen E, Price TJ, Shapiro J, Siu LL, Kubo M, Dobrovic A, Ratain MJ, Xu W, Mushiroda T, Liu G. Fc-gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer. Cancer Medicine 2018;7:5478-87.

49. Shetty A, Sparenberg S, Adams K, Selvedran S, Tang B, Hanna K, Iredell J. Arterial to end-tidal carbon dioxide tension difference (CO2 gap) as a prognostic marker for adverse outcomes in emergency department patients presenting with suspected sepsis. Emergency Medicine Australasia 2018;30:794-801.

50. Snow HA, Hitchen TX, Head J, Herschtal A, Bae S, Chander S, Chu J, Hendry S, Ngan SY, Desai J, Choong PFM, Henderson M, Gyorki DE. Treatment of patients with primary retroperitoneal sarcoma: predictors of outcome from an Australian specialist sarcoma centre. ANZ Journal of Surgery 2018;88:1151-7.

51. Socwell CP, Bucci L, Patchell S, Kotowicz E, Edbrooke L, Pope R. Utility of Mayo Clinic's early screen for discharge planning tool for predicting patient length of stay, discharge destination, and readmission risk in an inpatient oncology cohort. Supportive Care in Cancer 2018;26:3843-9.

52. Spigel DR, Chaft JE, Gettinger S, Chao BH, Dirix L, Schmid P, Chow LQM, Hicks RJ, Leon L, Fredrickson J, Kowanetz M, Sandler A, Funke R, Rizvi NA. FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients With NSCLC. Journal of Thoracic Oncology 2018;13:1733-42.

53. Sun Y, Reynolds HM, Wraith D, Williams S, Finnegan ME, Mitchell C, Murphy D, Haworth A. Voxel-wise prostate cell density prediction using multiparametric magnetic resonance imaging and machine learning. Acta Oncologica 2018;57:1540-6.

54. Teh BW, Tam CS, Handunnetti S, Worth LJ, Slavin MA. Infections in patients with chronic lymphocytic leukaemia: Mitigating risk in the era of targeted therapies. Blood Reviews 2018;32:499-507.

55. Thanarajasingam G, Minasian LM, Baron F, Cavalli F, De Claro RA, Dueck AC, El-Galaly TC, Everest N, Geissler J, Gisselbrecht C, Gribben J, Horowitz M, Ivy SP, Jacobson CA, Keating A, Kluetz PG, Krauss A, Kwong YL, Little RF, Mahon FX, Matasar MJ, Mateos MV, McCullough K, Miller RS, Mohty M, Moreau P, Morton LM, Nagai S, Rule S, Sloan J, Sonneveld P, Thompson CA, Tzogani K, van Leeuwen FE, Velikova G, Villa D, Wingard JR, Wintrich S, Seymour JF, Habermann TM. Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies. Lancet Haematology 2018;5:e563-e98.

56. Tio M, Rai R, Ezeoke OM, McQuade JL, Zimmer L, Khoo C, Park JJ, Spain L, Turajlic S, Ardolino L, Yip D, Goldinger SM, Cohen JV, Millward M, Atkinson V, Kane AY, Ascierto PA, Garbe C, Gutzmer R, Johnson DB, Rizvi HA, Joshua AM, Hellmann MD, Long GV, Menzies AM. Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection. European Journal of Cancer 2018;104:137-44.

57. Trubiano JA, Grayson ML, Phillips EJ, Stewardson AJ, Thursky KA, Slavin MA. Antibiotic allergy testing improves antibiotic appropriateness in patients with cancer. Journal of Antimicrobial Chemotherapy 2018;73:3209-11.

58. Turner NC, Slamon DJ, Ro J, Bondarenko I, Im SA, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, Andre F, Puyana Theall K, Huang X, Giorgetti C, Huang Bartlett C, Cristofanilli M. Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. New England Journal of Medicine 2018;379:1926-36.

59. Urbancic KF, Thursky K, Kong DCM, Johnson PDR, Slavin MA. Antifungal stewardship: developments in the field. Current Opinion in Infectious Diseases 2018;31:490-8.

60. Vissers JHA, Froldi F, Schroder J, Papenfuss AT, Cheng LY, Harvey KF. The Scalloped and Nerfin-1 Transcription Factors Cooperate to Maintain Neuronal Cell Fate. Cell Reports 2018;25:1561-76.e7.

61. Wainer Z, Wright GM, Gough K, Daniels MG, Russell PA, Choong P, Conron M, Ball D, Solomon B. Sex-Dependent Staging in Non-Small-Cell Lung Cancer; Analysis of the Effect of Sex Differences in the Eighth Edition of the Tumor, Node, Metastases Staging System. Clinical Lung Cancer 2018;19:e933-e44.

62. Walker AK, Martelli D, Ziegler AI, Lambert GW, Phillips SE, Hill SJ, McAllen RM, Sloan EK. Circulating epinephrine is not required for chronic stress to enhance metastasis. Psychoneuroendocrinology 2019;99:191-5.

63. Wasiak J, Hamilton DG, Foroudi F, Faggion CM, Jr. Surveying Retracted Studies and Notices Within the Field of Radiation Oncology. International Journal of Radiation Oncology, Biology, Physics 2018;102:660-5.

64. Wee E, Goh MS, Estall V, Tiong A, Webb A, Mitchell C, Murray W, Tran P, McCormack CJ, Henderson M, Hiscutt EL. Retrospective audit of patients referred for further treatment following Mohs surgery for non-melanoma skin cancer. Australasian Journal of Dermatology 2018;59:302-8.

65. Welz M, Eickhoff S, Abdullah Z, Trebicka J, Gartlan KH, Spicer JA, Demetris AJ, Akhlaghi H, Anton M, Manske K, Zehn D, Nieswandt B, Kurts C, Trapani JA, Knolle P, Wohlleber D, Kastenmuller W. Perforin inhibition protects from lethal endothelial damage during fulminant viral hepatitis. Nature Communications 2018;9:4805.

66. White VM, Skaczkowski G, Pinkerton R, Coory M, Osborn M, Bibby H, Nicholls W, Orme LM, Conyers R, Phillips MB, Harrup R, Walker R, Thompson K, Anazodo A. Clinical management of Australian adolescents and young adults with acute lymphoblastic and myeloid leukemias: A national population-based study. Pediatric Blood & Cancer 2018;65:e27349.

67. Willcox A, Wong E, Nath C, Janson B, Harrison SJ, Hoyt R, Bajel A, Shaw P, Ritchie D, Grigg A. The pharmacokinetics and pharmacodynamics of busulfan when combined with melphalan as conditioning in adult autologous stem cell transplant recipients. Annals of Hematology 2018;97:2509-18.

68. Wong HL, Christie M, Gately L, Tie J, Lee B, Semira C, Lok SW, Wong R, Gibbs P. Mismatch repair deficiency assessment by immunohistochemistry: for Lynch syndrome screening and beyond. Future Oncology 2018;14:2725-39.

69. Yong MK, Slavin MA, Kontoyiannis DP. Invasive fungal disease and cytomegalovirus infection: is there an association? Current Opinion in Infectious Diseases 2018;31:481-9.